Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to ...
Monte Rosa Therapeutics ( GLUE ) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +15.38% and +64.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. ( MIRM ) Surpasses Q3 Earnings and Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +150.00% and +0.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following ...
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of ...
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Amber International ( NASDAQ:AMBR ) , Adtran Holdings ( NASDAQ:ADTN )
U.S. stock futures were higher this morning, with the S&P 500 futures gaining around 0.2% on Tuesday. Shares of Dave & Buster's Entertainment Inc PLAY fell sharply in pre-market trading as the company posted weaker-than-expected results for the second quarter.
Monte Rosa Therapeutics ( GLUE ) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket - Adtran Holdings ( NASDAQ:ADTN ) , Apartment Inv & Mgmt ( NYSE:AIV )
Shares of Webtoon Entertainment Inc WBTN rose sharply in pre-market trading after announcing a partnership with The Walt Disney Co. DIS to build a digital comics platform that will bring together decades of Marvel, Star Wars, Pixar and Disney titles.
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Monte Rosa's volume jumps to 11.67 million vs. an average of 408K after announcing collaboration with Novartis. Monte Rosa gets $120 million upfront and could earn up to $5.7 billion in milestones and royalties. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio
Monte Rosa ( GLUE ) Q2 Revenue Jumps 394%
Monte Rosa Therapeutics ( NASDAQ:GLUE ) , a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million.
Monte Rosa Therapeutics ( GLUE ) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. ( CERT ) Q2 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces First Subjects Dosed in P1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader ...
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf ...
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-8102, a highly selective NEK7-directed molecular glue degrader ( MGD ) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I portfolio
Wall Street Analysts Think Monte Rosa Therapeutics ( GLUE ) Could Surge 222.16%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, May 28, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the ...
Monte Rosa Therapeutics ( GLUE ) Tops Q1 Earnings and Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 337.50% and 235.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. ( TCRX ) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 7.14% and 34.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. ( ARVN ) Q1 Earnings and Revenues Beat Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of 232.56% and 332.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research ( AACR ) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting ...
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Monte Rosa Therapeutics ( NASDAQ:GLUE )
MRT-6160 achieves over 90% VAV1 degradation in T and B cells. Monte Rosa's $150 million deal with Novartis could bring up to $2.1 billion in milestone payments. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
Monte Rosa Therapeutics ( GLUE ) Q4 Earnings and Revenues Top Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa ...
3 Top Cancer Biotechs to Keep An Eye On in 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - Monte Rosa Therapeutics ( NASDAQ:GLUE )
Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader ( MGD ) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Monte Rosa Therapeutics ( NASDAQ:GLUE )
BOSTON, Dec. 13, 2024 ( GLOBE NEWSWIRE ) -- Monte Rosa Therapeutics, Inc. GLUE, a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors.
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Closing of Global License Agreement with ...
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue ...
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients
Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics ( GLUE ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
BOSTON, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- ( Nasdaq: GLUE ) , a clinical-stage biotechnology company developing novel molecular glue degrader ( MGD ) -based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the 36th Annual ...
Wall Street Analysts Think Monte Rosa Therapeutics ( GLUE ) Could Surge 100.47%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics ( GLUE ) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics ( GLUE ) is a Great Choice
Does Monte Rosa Therapeutics (GLUE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Monte Rosa Therapeutics ( GLUE ) Could Rally 67.24%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Novartis Ag ( NVS ) Q3 2024 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2024.
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation PRCT rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Monte Rosa Therapeutics ( NASDAQ:GLUE ) , Novartis ( NYSE:NVS )
Monte Rosa Therapeutics Inc GLUE stock is trading higher on Monday after the company announced a global exclusive development and commercialization license agreement with Novartis AG NVS to advance VAV1 MGDs, including MRT-6160.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ...
